December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian…
CEO Speaks: On the major milestone for Biocon-Sandoz and how this collaboration will enable Biocon to address the next wave of Global Biosimilar Opportunities!
Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
Biocon reported strong Q2FY17 results. Small Molecules, Biologics and Research Services businesses showed strong growth while it was a stand-out quarter for the Biologics business.
Part 2 – The potential financial benefits and better health outcomes from biosimilars use could spur their uptake in health systems globally.
Part 1 – Biosimilars can provide cost-effective, high quality alternatives to expensive reference biologics, thus improving access and expanding the patient base.